Slope and LabConnect have accelerated their strategic partnership with multiple joint customers launching API-integrated clinical trials in December 2025, spanning diverse therapeutic areas. The bidirectional API integration unifies real-time data exchange between site-level biospecimen management and central laboratory systems, driving operational precision, reducing lab kit waste by an average of 71%, achieving 98% site adoption rates on sponsor-contracted studies, and cutting lab queries by up to 98%. Additional trials are slated to activate in early 2026, extending the model to support advanced workflows such as lab-to-lab transfers and decentralized trial configurations.
Partnership Momentum Builds on Proven Integration
The collaboration between Slope and LabConnect has evolved rapidly since the initial rollout of their bidirectional API integration. This technology connects Slope’s site-facing platform directly with LabConnect’s Laboratory Information Management System (LIMS), enabling seamless electronic data exchange for lab kit and bulk supply ordering, inventory visibility, sample shipment tracking, and the transfer of critical sample and subject metadata. By bridging site, sponsor, and laboratory workflows through Slope’s vendor-agnostic, lab-validated technology, the integration addresses longstanding fragmentation in clinical operations.
In the months following the API’s introduction, the focus shifted from technical deployment to practical application. Multiple sponsors across various therapeutic areas adopted the joint solution for their studies, culminating in several trials going live during December 2025. These activations demonstrate the integration’s reliability in real-world settings, where study teams require precise control over inventory and sample integrity to maintain protocol adherence and accelerate timelines.
Real-World Impact of API-Enabled Trials
The trials launched in Q4 2025 highlight the integration’s ability to support complex, sample-intensive protocols. Sponsors benefit from automated workflows that replace manual processes prone to errors and delays. For instance, lab kit resupply orders generated by LabConnect flow directly into Slope, providing full visibility and control at the site level. Study teams can configure customizable inventory thresholds per site and protocol, implement approval workflows, and monitor status via centralized dashboards and reports.
Inventory shipments from LabConnect to sites are digitized end-to-end. Inbound supply manifests and package-level delivery tracking become visible in real time to both sites and sponsors. Upon arrival, inventory counts update automatically. As patient visits proceed, samples are registered, or items expire, counts adjust instantaneously—eliminating manual reporting of expired kits and bridging gaps between collection and laboratory receipt.
Proactive alerts notify teams of low stock or impending expirations, preventing shortages that could jeopardize patient enrollment or data collection. On the sample side, sites move away from traditional lab manuals toward Slope’s guided digital workflows for collection, processing, storage, and shipment. Electronic capture of subject, visit, and sample metadata streamlines registration in LabConnect’s LIMS, removes paper requisition forms, enables pre-accessioning to flag discrepancies before shipments arrive, and reduces downstream queries and delays.
This joint approach accommodates advanced operational models. In trials involving home health services, mobile nurses, or satellite hubs, supplies can be tracked across multiple shipping addresses per site. Large academic centers and decentralized trial designs benefit from simplified multi-location inventory management, ensuring consistency regardless of collection location.
Quantifiable Gains in Efficiency and Cost Control
The integration delivers measurable improvements that directly impact trial economics. Slope’s broader platform, now enhanced by the LabConnect connection, has established benchmarks across its network:
Average 71% reduction in lab kit waste through precise inventory tracking and data-driven reordering
98% site adoption rate on sponsor-contracted trials, reflecting ease of use and minimal disruption
Up to 98% fewer lab queries due to automated, error-free metadata transfer and pre-accessioning
These outcomes translate into substantial cost savings for sponsors. Clinical trials often face overruns from supply mismanagement, sample mishandling, or data discrepancies—issues that inflate budgets and extend timelines. By unifying the biospecimen lifecycle—from logistics and collection through processing, storage, shipment, and integration with electronic data capture (EDC) systems and lab databases—the integrated model mitigates risks, accelerates cycle times, and supports higher-quality data generation.
Executive Perspectives on the Advancement
Leaders from both companies emphasized the partnership’s progression from concept to execution. Jim Munz, Chief Product and Technology Officer at Slope, highlighted the transition to tangible results: “Over the past year, we’ve moved from announcing the API to demonstrating real-world impact for sponsors launching trials via the Slope + LabConnect integration. The clinical trials span diverse therapeutic areas and demonstrate that seamless integration between sample management solutions and central labs can improve efficiency across clinical operations.”
Charles Castano, Chief Technology Officer at LabConnect, underscored the ecosystem benefits: “This partnership strengthens LabConnect’s ability to deliver biospecimen excellence through our broader, more connected technology ecosystem. Slope provides site-level inventory and sample management that integrates into our existing laboratory and data infrastructure without requiring new hardware. The integration also gives us access to Slope’s network of 2,200+ sites already utilizing the platform, which has driven a 98% site adoption rate on sponsor-contracted trials.”
Looking Ahead: Expanded Capabilities
The partnership shows no signs of slowing. Additional studies are scheduled to activate in early 2026, broadening adoption across more sponsors and protocols. Plans include extending the integration to support further sample-tracking workflows, with enhancements for lab-to-lab transfers targeted for release starting in early 2026. These developments will enable more holistic biospecimen oversight, particularly in multi-lab scenarios common in global or specialty testing programs.
As clinical research grows more complex—with rising emphasis on precision medicine, oncology, vaccines, and decentralized models—the demand for integrated, technology-driven solutions intensifies. The Slope-LabConnect model positions both organizations to meet this need, offering sponsors greater precision, flexibility, and speed in bringing therapies to market.
Disclaimer: This article is a news report on developments in the clinical research and biotechnology sectors. It is provided for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation to buy or sell any securities.